Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up

Psychopharmacology

Volumn 191, Issue 4, 2007, Pages 1023-1026

  Nickel, Marius K ^a,b   Loew, Thomas H ^c   Gil, Francisco Pedrosa ^d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aripiprazole; Borderline personality disorder; Hamilton depression rating scale

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ANXIETY; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MALE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RATING SCALE; RESTLESSNESS; SIDE EFFECT; STATE-TRAIT ANGER EXPRESSION INVENTORY; SYMPTOM CHECKLIST 90; WEIGHT CHANGE;

ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947109416     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0740-0     Document Type: Article

References (15)

1. Briley M, Moret C (1993) Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 16:387-400
2. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66:49-51
3. Franke GH (2002) SCL-90-R: Symptom-Checkliste von L.R. Derogatis. Goettingen, Beltz
4. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
5. Hamilton M (1976) Development of a rating scale; for primary depressive illness. Br J Soc Clin Psychol 6:278-296
6. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology 182:220-231
7. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325-337
8. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651-1658
9. Jagadheesan K, Muirhead D (2004) Aripiprazole for acute mania. Am J Psychiatry 161:1926-1927
10. Mobascher A, Mobascher J, Schlemper V, Winterer G, Malevani J (2006) Aripiprazole pharmacotherapy of borderline personality disorder. Phaarmacopsychiatry 39:111-112
11. Nickel M, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, C Egger, Anvar J, Rother W, Loew T, Kaplan P (2006) Aripiprazole in treatment of borderline patients: a double-blind, placebo-controlled study. Am J Psychiatry 163:833-838
12. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E. Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690
13. Schwenkmezger, P, Hodapp, V, Spielberger, CD (1992) The State-Trait Anger Expression Inventory. Goettingen, Bern
14. Stevens J (1992) Applied multivariate statistics for the social sciences. Erlbaum, New Jersey
15. Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J (2003) Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSMIV borderline psychopathology. J Personal Disord 17:233-242